Microbiome

Microbiome Epidemiology

Microbiome epidemiology still suffers from measurement and population heterogeneity, method standardization and authority issues. However, its mechanistic interpretation has already been very successful in settings ranging from drug metabolism to immunity. Measuring the composition of the Microbiome (which taxa/species are present) is most commonly addressed using amplicon-based/marker gene sequencing approaches to conduct microbial populations [45, 46] across a variety of samples and treatments. An imbalance of the normal gut Micro biome is associated with a wide range of systemic manifestations of gastrointestinal conditions such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and diseases such as obesity, type-2 diabetes and autopsy.